It included a prospective case-control study, adding to original API (but replacing eosinophilia by specific IgE) the following parameters: 17 exhaled volatile organic compounds (collected and detected by gas chromatography–time of flight–mass spectrometry), 10 exhaled breath condensate biomarkers (cytokines and chemokines analyzed with a multiplex immunoassay), 31 genes expression, and lung function measured by airway resistance using MicroRint®. This evidence concerns the gene IGHE and Increased total eosinophil count.